PMID- 9766747
OWN - NLM
STAT- MEDLINE
DCOM- 19981020
LR  - 20190826
IS  - 0145-2126 (Print)
IS  - 0145-2126 (Linking)
VI  - 22
IP  - 10
DP  - 1998 Oct
TI  - Interferon-alpha for the treatment of elderly patients with chronic myeloid 
      leukaemia.
PG  - 881-6
AB  - The present retrospective analysis is based on data of 213 patients with chronic 
      myeloid leukaemia (CML). They were treated with interferon (IFN)alpha-2C 
      (Berofor) at daily doses of 3.5 MU subcutaneously (s.c.), alone or in combination 
      with low-dose ara-C or hydroxyurea, according to four consecutive studies of the 
      Austrian CML Study Group. Comparisons were made between 41 patients aged > or = 
      60 years and 172 younger patients. The elderly patients (median: 64 years; range: 
      60-73) showed similar pretreatment characteristics compared with the younger 
      group, but included a higher percentage of Sokal Stage three (51 vs 20%). Median 
      observation periods were similar (38 vs 39 months), whereas the duration of 
      IFNalpha treatment was shorter in the elderly group (median 57 vs 42 weeks). The 
      rate of overall haematological responses (73 vs 78%) and complete haematological 
      response (44 vs 54%), was similar in both cohorts. Differences seen in partial (5 
      vs 12%) and complete cytogenetic response (10 vs 13%), were not statistically 
      significant, but a tendency in favour of the younger cohort had to be noted. 
      Summing up, in elderly patients acceptable rates of haematological and cytogentic 
      response can be expected after treatment with IFNalpha alone or in combination 
      with LD ara-C or HU.
FAU - Hilbe, W
AU  - Hilbe W
AD  - Department of Internal Medicine, University Hospital, Innsbruck, Austria.
FAU - Apfelbeck, U
AU  - Apfelbeck U
FAU - Fridrik, M
AU  - Fridrik M
FAU - Bernhart, M
AU  - Bernhart M
FAU - Niessner, H
AU  - Niessner H
FAU - Abbrederis, K
AU  - Abbrederis K
FAU - Michlmayr, G
AU  - Michlmayr G
FAU - Pont, J
AU  - Pont J
FAU - Linkesch, W
AU  - Linkesch W
FAU - Hausmaninger, H
AU  - Hausmaninger H
FAU - Arneitz, K
AU  - Arneitz K
FAU - Baldinger, C
AU  - Baldinger C
FAU - Duba, C
AU  - Duba C
FAU - Eisterer, W
AU  - Eisterer W
FAU - Greil, R
AU  - Greil R
FAU - Konwalinka, G
AU  - Konwalinka G
FAU - Niederwieser, D
AU  - Niederwieser D
FAU - Gastl, G
AU  - Gastl G
FAU - Thaler, J
AU  - Thaler J
LA  - eng
PT  - Journal Article
PL  - England
TA  - Leuk Res
JT  - Leukemia research
JID - 7706787
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Interferon-alpha)
RN  - 04079A1RDZ (Cytarabine)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Child
MH  - Child, Preschool
MH  - Cytarabine/administration & dosage
MH  - Humans
MH  - Hydroxyurea/administration & dosage
MH  - Interferon-alpha/adverse effects/*therapeutic use
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/mortality
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 1998/10/10 00:00
MHDA- 1998/10/10 00:01
CRDT- 1998/10/10 00:00
PHST- 1998/10/10 00:00 [pubmed]
PHST- 1998/10/10 00:01 [medline]
PHST- 1998/10/10 00:00 [entrez]
AID - S0145212698000642 [pii]
AID - 10.1016/s0145-2126(98)00064-2 [doi]
PST - ppublish
SO  - Leuk Res. 1998 Oct;22(10):881-6. doi: 10.1016/s0145-2126(98)00064-2.